Stock of the Day

Today's Trend

Novavax, Inc. (NASDAQ: NVAX) shares increased as biotechnology stocks rallied broadly and investors responded to fading concerns about a suspected pneumonic plague case in Russia. The move appears largely sentiment-driven rather than the result of a new Novavax-specific business announcement.

• Broad biotech rally: Vaccine and biotechnology stocks advanced, with Novavax among the strongest performers. Positive momentum across the sector likely attracted momentum traders and helped lift NVAX on unusually heavy volume. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive vaccine-sector sentiment: Moderna’s rally following reports of a planned national cancer-vaccine effort renewed investor interest in vaccine developers generally. Although the initiative is not a Novavax project, the enthusiasm may have benefited the broader vaccine group. Moderna Stock Hits 4-Year High on Planned National Cancer Vaccine Effort
• Plague fears eased: Reports emphasizing the World Health Organization’s assessment that epidemic risk was low reduced a short-term source of uncertainty. Earlier headlines had driven sharp volatility in NVAX despite no direct change to the company’s vaccine portfolio. Novavax Headline-Driven Volatility Around Russia Health Scare
• Investor attention increased: Zacks reported elevated user interest in NVAX, but provided no new fundamental catalyst. Greater visibility can support trading activity while also increasing volatility. Novavax Is Attracting Investor Attention
• Analyst remains cautious: BofA raised its price target to $8 from $7 but maintained an Underperform rating, indicating that the firm still views the recent share price as above its fundamental expectations. BofA Adjusts Price Target on Novavax
• Fundamental and valuation risks: Commentary warned that the rebound may have moved NVAX above fair value, while Novavax’s longer-term growth prospects remain exposed to weak sales and execution risks. Novavax Vaccine Maker Sees Momentum in 2026 but Growth Story Holds Fundamental Risks